Plasma Therapy Market Research Report by Type (Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin, and Leukocyte-Rich Fibrin), by Source (Autologous, Allogenic), by Application (Orthopedic, Dermatology, Cardiac Muscle Injury, Dental, Nerve Injury), End Users (Hospitals & Clinics and Research Institutions) and by Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast to 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Techniques

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Impact on Supply Chain

5.3.3. Regional Impact

5.3.4. Opportunity and Threat Analysis

6. GLOBAL PLASMA THERAPY MARKET, BY TYPE

6.1. Introduction

6.2. Pure Plasma Rich Protein (PRP)

6.3. Leukocyte-Rich PRP

6.4. Pure Platelet-Rich Fibrin

6.5. Leukocyte-Rich Fibrin

7. GLOBAL PLASMA THERAPY MARKET, BY SOURCE

7.1. Introduction

7.2. Autologous

7.3. Allogenic

8. GLOBAL PLASMA THERAPY MARKET, BY APPLICATION

8.1. Introduction

8.2. Orthopedic

8.3. Dermatology

8.4. Cardiac Muscle Injury

8.5. Dental

8.6. Nerve Injury

9. GLOBAL PLASMA THERAPY MARKET, BY END USER

9.1. Introduction

9.2. Hospitals & Clinics

9.3. Research Institutes

10. GLOBAL PLASMA THERAPY MARKET, BY REGION

10.1. Overview

10.2. North America

10.2.1. Market Size & Estimates, by Country, 2018–2030

10.2.2. Market Size & Estimates, by Type, 2018–2030

10.2.3. Market Size & Estimates, by Source, 2018–2030

10.2.4. Market Size & Estimates, by Application, 2018–2030

10.2.5. Market Size & Estimates, by End User, 2018–2030

10.2.6. US

10.2.6.1. Market Size & Estimates, by Type, 2018–2030

10.2.6.2. Market Size & Estimates, by Source, 2018–2030

10.2.6.3. Market Size & Estimates, by Application, 2018–2030

10.2.6.4. Market Size & Estimates, by End User, 2018–2030

10.2.7. Canada

10.2.7.1. Market Size & Estimates, by Type, 2018–2030

10.2.7.2. Market Size & Estimates, by Source, 2018–2030

10.2.7.3. Market Size & Estimates, by Application, 2018–2030

10.2.7.4. Market Size & Estimates, by End User, 2018–2030

10.3. Europe

10.3.1. Market Size & Estimates, by Country, 2018–2030

10.3.2. Market Size & Estimates, by Type, 2018–2030

10.3.3. Market Size & Estimates, by Source, 2018–2030

10.3.4. Market Size & Estimates, by Application, 2018–2030

10.3.5. Market Size & Estimates, by End User, 2018–2030

10.3.6. Germany

10.3.6.1. Market Size & Estimates, by Type, 2018–2030

10.3.6.2. Market Size & Estimates, by Source, 2018–2030

10.3.6.3. Market Size & Estimates, by Application, 2018–2030

10.3.6.4. Market Size & Estimates, by End User, 2018–2030

10.3.7. France

10.3.7.1. Market Size & Estimates, by Type, 2018–2030

10.3.7.2. Market Size & Estimates, by Source, 2018–2030

10.3.7.3. Market Size & Estimates, by Application, 2018–2030

10.3.7.4. Market Size & Estimates, by End User, 2018–2030

10.3.8. UK

10.3.8.1. Market Size & Estimates, by Type, 2018–2030

10.3.8.2. Market Size & Estimates, by Source, 2018–2030

10.3.8.3. Market Size & Estimates, by Application, 2018–2030

10.3.8.4. Market Size & Estimates, by End User, 2018–2030

10.3.9. Italy

10.3.9.1. Market Size & Estimates, by Type, 2018–2030

10.3.9.2. Market Size & Estimates, by Source, 2018–2030

10.3.9.3. Market Size & Estimates, by Application, 2018–2030

10.3.9.4. Market Size & Estimates, by End User, 2018–2030

10.3.10. Spain

10.3.10.1. Market Size & Estimates, by Type, 2018–2030

10.3.10.2. Market Size & Estimates, by Source, 2018–2030

10.3.10.3. Market Size & Estimates, by Application, 2018–2030

10.3.10.4. Market Size & Estimates, by End User, 2018–2030

10.3.11. Rest of Europe

10.3.11.1. Market Size & Estimates, by Type, 2018–2030

10.3.11.2. Market Size & Estimates, by Source, 2018–2030

10.3.11.3. Market Size & Estimates, by Application, 2018–2030

10.3.11.4. Market Size & Estimates, by End User, 2018–2030

10.4. Asia-Pacific

10.4.1. Market Size & Estimates, by Country, 2018–2030

10.4.2. Market Size & Estimates, by Type, 2018–2030

10.4.3. Market Size & Estimates, by Source, 2018–2030

10.4.4. Market Size & Estimates, by Application, 2018–2030

10.4.5. Market Size & Estimates, by End User, 2018–2030

10.4.6. China

10.4.6.1. Market Size & Estimates, by Type, 2018–2030

10.4.6.2. Market Size & Estimates, by Source, 2018–2030

10.4.6.3. Market Size & Estimates, by Application, 2018–2030

10.4.6.4. Market Size & Estimates, by End User, 2018–2030

10.4.7. Japan

10.4.7.1. Market Size & Estimates, by Type, 2018–2030

10.4.7.2. Market Size & Estimates, by Source, 2018–2030

10.4.7.3. Market Size & Estimates, by Application, 2018–2030

10.4.7.4. Market Size & Estimates, by End User, 2018–2030

10.4.8. India

10.4.8.1. Market Size & Estimates, by Type, 2018–2030

10.4.8.2. Market Size & Estimates, by Source, 2018–2030

10.4.8.3. Market Size & Estimates, by Application, 2018–2030

10.4.8.4. Market Size & Estimates, by End User, 2018–2030

10.4.9. South Korea

10.4.9.1. Market Size & Estimates, by Type, 2018–2030

10.4.9.2. Market Size & Estimates, by Source, 2018–2030

10.4.9.3. Market Size & Estimates, by Application, 2018–2030

10.4.9.4. Market Size & Estimates, by End User, 2018–2030

10.4.10. Australia

10.4.10.1. Market Size & Estimates, by Type, 2018–2030

10.4.10.2. Market Size & Estimates, by Source, 2018–2030

10.4.10.3. Market Size & Estimates, by Application, 2018–2030

10.4.10.4. Market Size & Estimates, by End User, 2018–2030

10.4.11. Rest of Asia-Pacific

10.4.11.1. Market Size & Estimates, by Type, 2018–2030

10.4.11.2. Market Size & Estimates, by Source, 2018–2030

10.4.11.3. Market Size & Estimates, by Application, 2018–2030

10.4.11.4. Market Size & Estimates, by End User, 2018–2030

10.5. Rest of the World

10.5.1. Market Size & Estimates, by Country, 2018–2030

10.5.2. Market Size & Estimates, by Type, 2018–2030

10.5.3. Market Size & Estimates, by Source, 2018–2030

10.5.4. Market Size & Estimates, by Application, 2018–2030

10.5.5. Market Size & Estimates, by End User, 2018–2030

10.5.6. Middle East

10.5.6.1. Market Size & Estimates, by Type, 2018–2030

10.5.6.2. Market Size & Estimates, by Source, 2018–2030

10.5.6.3. Market Size & Estimates, by Application, 2018–2030

10.5.6.4. Market Size & Estimates, by End User, 2018–2030

10.5.7. Africa

10.5.7.1. Market Size & Estimates, by Type, 2018–2030

10.5.7.2. Market Size & Estimates, by Source, 2018–2030

10.5.7.3. Market Size & Estimates, by Application, 2018–2030

10.5.7.4. Market Size & Estimates, by End User, 2018–2030

10.5.8. Latin America

10.5.8.1. Market Size & Estimates, by Type, 2018–2030

10.5.8.2. Market Size & Estimates, by Source, 2018–2030

10.5.8.3. Market Size & Estimates, by Application, 2018–2030

10.5.8.4. Market Size & Estimates, by End User, 2018–2030

11. COMPETITIVE LANDSCAPE

11.1. Introduction

11.2. Key Players Market Share Analysis, 2020 (%)

11.3. Competitive Benchmarking

11.4. Competitor Dashboard

11.5. Major Growth Strategy in the Market

11.6. Key Developments & Growth Strategies

11.6.1. Product Developments

11.6.2. Mergers & Acquisitions

11.6.3. Contracts & Agreements

12. COMPANY PROFILES

12.1. BioLife Plasma Services (US)

12.1.1. Company Overview

12.1.2. Financial Overview

12.1.3. Software/Solutions Offered

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Cambryn Biologics LLC (US)

12.2.1. Company Overview

12.2.2. Financial Overview

12.2.3. Software/Solutions Offered

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. Biotest (Germany)

12.3.1. Company Overview

12.3.2. Financial Overview

12.3.3. Software/Solutions Offered

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.4. CSL Ltd. (Australia)

12.4.1. Company Overview

12.4.2. Financial Overview

12.4.3. Software/Solutions Offered

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. Grifols International S.A. (Spain)

12.5.1. Company Overview

12.5.2. Financial Overview

12.5.3. Software/Solutions Offered

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. Kedrion S.p.A. (Italy)

12.6.1. Company Overview

12.6.2. Financial Overview

12.6.3. Software/Solutions Offered

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. LFB S.A (France)

12.7.1. Company Overview

12.7.2. Financial Overview

12.7.3. Software/Solutions Offered

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. Bio Products Laboratory Ltd. (U.K.)

12.8.1. Company Overview

12.8.2. Financial Overview

12.8.3. Software/Solutions Offered

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. China Biologic Products, Inc. (China)

12.9.1. Company Overview

12.9.2. Financial Overview

12.9.3. Software/Solutions Offered

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. Octapharma (Switzerland)

12.10.1. Company Overview

12.10.2. Financial Overview

12.10.3. Software/Solutions Offered

12.10.4. Key Developments

12.10.5. SWOT Analysis

12.10.6. Key Strategies

12.11. Arthrex, Inc. (US)

12.11.1. Company Overview

12.11.2. Financial Overview

12.11.3. Software/Solutions Offered

12.11.4. Key Developments

12.11.5. SWOT Analysis

12.11.6. Key Strategies

12.12. DePuy Synthes Companies (US)

12.12.1. Company Overview

12.12.2. Financial Overview

12.12.3. Software/Solutions Offered

12.12.4. Key Developments

12.12.5. SWOT Analysis

12.12.6. Key Strategies

12.13. Grifols S.A (Spain)

12.13.1. Company Overview

12.13.2. Financial Overview

12.13.3. Software/Solutions Offered

12.13.4. Key Developments

12.13.5. SWOT Analysis

12.13.6. Key Strategies

12.14. Global Stem Cells Group, Inc. (US)

12.14.1. Company Overview

12.14.2. Financial Overview

12.14.3. Software/Solutions Offered

12.14.4. Key Developments

12.14.5. SWOT Analysis

12.14.6. Key Strategies

12.15. Juventix Regenerative Medical LLC (U.S.)

12.15.1. Company Overview

12.15.2. Financial Overview

12.15.3. Software/Solutions Offered

12.15.4. Key Developments

12.15.5. SWOT Analysis

12.15.6. Key Strategies

12.16. Celling Biosciences, Inc. (U.S.)

12.16.1. Company Overview

12.16.2. Financial Overview

12.16.3. Software/Solutions Offered

12.16.4. Key Developments

12.16.5. SWOT Analysis

12.16.6. Key Strategies

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS

TABLE 2 GLOBAL PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 3 GLOBAL PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 4 GLOBAL PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 5 GLOBAL PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 6 GLOBAL PLASMA THERAPY MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 7 NORTH AMERICA PLASMA THERAPY MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 8 NORTH AMERICA PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 9 NORTH AMERICA PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 10 NORTH AMERICA PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 11 NORTH AMERICA PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 12 US PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 13 US PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 14 US PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 15 US PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 16 CANADA PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 17 CANADA PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 18 CANADA PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 19 CANADA PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 20 EUROPE PLASMA THERAPY MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 21 EUROPE PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 22 EUROPE PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 23 EUROPE PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 24 EUROPE PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 25 GERMANY PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 26 GERMANY PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 27 GERMANY PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 28 GERMANY PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 29 FRANCE PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 30 FRANCE PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 31 FRANCE PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 32 FRANCE PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 33 UK PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 34 UK PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 35 UK PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 36 UK PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 37 ITALY PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 38 ITALY PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 39 ITALY PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 40 ITALY PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 41 SPAIN PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 42 SPAIN PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 43 SPAIN PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 44 SPAIN PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 45 REST OF EUROPE PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 46 REST OF EUROPE PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 47 REST OF EUROPE PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 48 REST OF EUROPE PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 49 ASIA-PACIFIC PLASMA THERAPY MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 50 ASIA-PACIFIC PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 51 ASIA-PACIFIC PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 52 ASIA-PACIFIC PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 53 ASIA-PACIFIC PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 54 CHINA PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 55 CHINA PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 56 CHINA PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 57 CHINA PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 58 INDIA PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 59 INDIA PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 60 INDIA PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 61 INDIA PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 62 JAPAN PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 63 JAPAN PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 64 JAPAN PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 65 JAPAN PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 66 AUSTRALIA PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 67 AUSTRALIA PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 68 AUSTRALIA PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 69 AUSTRALIA PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 70 SOUTH KOREA PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 71 SOUTH KOREA PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 72 SOUTH KOREA PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 73 SOUTH KOREA PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 74 REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 75 REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 76 REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 77 REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 78 REST OF THE WORLD PLASMA THERAPY MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 79 REST OF THE WORLD PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 80 REST OF THE WORLD PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 81 REST OF THE WORLD PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 82 REST OF THE WORLD PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 83 MIDDLE EAST PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 84 MIDDLE EAST PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 85 MIDDLE EAST PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 86 MIDDLE EAST PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 87 AFRICA PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 88 AFRICA PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 89 AFRICA PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 90 AFRICA PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 91 LATIN AMERICA PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 92 LATIN AMERICA PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

TABLE 93 LATIN AMERICA PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 94 LATIN AMERICA PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS

FIGURE 2 RESEARCH PROCESS OF MRFR

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH

FIGURE 4 GLOBAL PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 5 GLOBAL PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 6 GLOBAL PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 7 GLOBAL PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 8 GLOBAL PLASMA THERAPY MARKET, BY REGION, 2018–2030 (USD MILLION)

FIGURE 9 NORTH AMERICA PLASMA THERAPY MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

FIGURE 10 NORTH AMERICA PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 11 NORTH AMERICA PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 12 NORTH AMERICA PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 13 NORTH AMERICA PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 14 US PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 15 US PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 16 US PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 17 US PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 18 CANADA PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 19 CANADA PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 20 CANADA PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 21 CANADA PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 22 EUROPE PLASMA THERAPY MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

FIGURE 23 EUROPE PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 24 EUROPE PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 25 EUROPE PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 26 EUROPE PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 27 GERMANY PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 28 GERMANY PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 29 GERMANY PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 30 GERMANY PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 31 FRANCE PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 32 FRANCE PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 33 FRANCE PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 34 FRANCE PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 35 UK PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 36 UK PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 37 UK PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 38 UK PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 39 ITALY PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 40 ITALY PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 41 ITALY PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 42 ITALY PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 43 SPAIN PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 44 SPAIN PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 45 SPAIN PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 46 SPAIN PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 47 REST OF EUROPE PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 48 REST OF EUROPE PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 49 REST OF EUROPE PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 50 REST OF EUROPE PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 51 ASIA-PACIFIC PLASMA THERAPY MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

FIGURE 52 ASIA-PACIFIC PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 53 ASIA-PACIFIC PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 54 ASIA-PACIFIC PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 55 ASIA-PACIFIC PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 56 CHINA PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 57 CHINA PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 58 CHINA PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 59 CHINA PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 60 INDIA PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 61 INDIA PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 62 INDIA PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 63 INDIA PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 64 JAPAN PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 65 JAPAN PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 66 JAPAN PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 67 JAPAN PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 68 AUSTRALIA PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 69 AUSTRALIA PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 70 AUSTRALIA PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 71 AUSTRALIA PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 72 SOUTH KOREA PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 73 SOUTH KOREA PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 74 SOUTH KOREA PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 75 SOUTH KOREA PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 76 REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 77 REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 78 REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 79 REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 80 REST OF THE WORLD PLASMA THERAPY MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

FIGURE 81 REST OF THE WORLD PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 82 REST OF THE WORLD PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 83 REST OF THE WORLD PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 84 REST OF THE WORLD PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 85 MIDDLE EAST PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 86 MIDDLE EAST PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 87 MIDDLE EAST PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 88 MIDDLE EAST PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 89 AFRICA PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 90 AFRICA PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 91 AFRICA PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 92 AFRICA PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)

FIGURE 93 LATIN AMERICA PLASMA THERAPY MARKET, BY TYPE, 2018–2030 (USD MILLION)

FIGURE 94 LATIN AMERICA PLASMA THERAPY MARKET, BY SOURCE, 2018–2030 (USD MILLION)

FIGURE 95 LATIN AMERICA PLASMA THERAPY MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

FIGURE 96 LATIN AMERICA PLASMA THERAPY MARKET, BY END-USER, 2018–2030 (USD MILLION)